CRISPR Therapeutics AG financial data

Symbol
CRSP on Nasdaq
Location
Baarerstrasse 14, Zug, Switzerland
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.73K % -3.22%
Debt-to-equity 17.5 % +0.34%
Return On Equity -26.4 % -118%
Return On Assets -22.5 % -117%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 95.3M shares +11.7%
Common Stock, Shares, Outstanding 93.9M shares +10%
Entity Public Float 4.3B USD +4.88%
Common Stock, Value, Issued 3.01M USD +12.3%
Weighted Average Number of Shares Outstanding, Basic 91.3M shares +7.12%
Weighted Average Number of Shares Outstanding, Diluted 91.3M shares +7.12%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 38.3M USD -81.1%
Research and Development Expense 283M USD -15%
General and Administrative Expense 73.3M USD +2.71%
Operating Income (Loss) -574M USD -72.8%
Nonoperating Income (Expense) 89.8M USD -6.36%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -485M USD -105%
Income Tax Expense (Benefit) 3.72M USD +19.2%
Net Income (Loss) Attributable to Parent -488M USD -104%
Earnings Per Share, Basic -5 USD/shares -97.9%
Earnings Per Share, Diluted -5 USD/shares -97.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 286M USD +27%
Marketable Securities, Current 1.63B USD -4.72%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Assets, Current 1.93B USD -0.76%
Property, Plant and Equipment, Net 121M USD -12.8%
Operating Lease, Right-of-Use Asset 135M USD -7.95%
Other Assets, Noncurrent 24.3M USD +53%
Assets 2.25B USD -0.48%
Accounts Payable, Current 11.8M USD -24.3%
Employee-related Liabilities, Current 10.2M USD -32.8%
Accrued Liabilities, Current 84.2M USD +78.3%
Contract with Customer, Liability, Current 1.3M USD -71.1%
Liabilities, Current 119M USD +32.5%
Contract with Customer, Liability, Noncurrent 12.3M USD 0%
Operating Lease, Liability, Noncurrent 193M USD -8.49%
Other Liabilities, Noncurrent 5.28M USD +43.5%
Liabilities 329M USD +4.06%
Accumulated Other Comprehensive Income (Loss), Net of Tax 4.99M USD -52.8%
Retained Earnings (Accumulated Deficit) -1.82B USD -36.8%
Stockholders' Equity Attributable to Parent 1.92B USD -1.22%
Liabilities and Equity 2.25B USD -0.48%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -53.9M USD -149%
Net Cash Provided by (Used in) Financing Activities 10.6M USD -96.5%
Net Cash Provided by (Used in) Investing Activities -19.8M USD +79.8%
Common Stock, Shares Authorized 132M shares 0%
Common Stock, Shares, Issued 94M shares +9.93%
Common Stock, Par or Stated Value Per Share 0.03 CHF/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -63.1M USD -120%
Deferred Tax Assets, Valuation Allowance 283M USD +24.2%
Deferred Tax Assets, Gross 355M USD +15.5%
Operating Lease, Liability 224M USD -6.26%
Depreciation 18.5M USD -4.15%
Payments to Acquire Property, Plant, and Equipment 206K USD -71.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -494M USD -122%
Lessee, Operating Lease, Liability, to be Paid 295M USD -8.68%
Property, Plant and Equipment, Gross 206M USD +0.05%
Operating Lease, Liability, Current 18.3M USD +8.13%
Lessee, Operating Lease, Liability, to be Paid, Year Two 29.5M USD +2.23%
Lessee, Operating Lease, Liability, to be Paid, Year One 29.4M USD +2.48%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 70.9M USD -15.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 28.7M USD -2.37%
Deferred Tax Assets, Operating Loss Carryforwards 178M USD +33.5%
Unrecognized Tax Benefits 50M USD +13.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 28.2M USD -1.78%
Depreciation, Depletion and Amortization 4.74M USD -2.01%
Deferred Tax Assets, Net of Valuation Allowance 72.7M USD -9.26%
Share-based Payment Arrangement, Expense 76.4M USD -8.03%